SCIENTURE HOLDINGS INC (SCNX) Stock News

USA - NASDAQ:SCNX - US80880X1046 - Common Stock

0.5351 USD

-0.05 (-9.29%)

Last: 10/17/2025, 8:00:02 PM

0.5005 USD

-0.03 (-6.47%)

After Hours: 10/17/2025, 8:00:02 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

SCNX Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Scienture Holdings, Inc.

SCIENTURE’S Arbli™ Becomes First FDA-Approved Ready-to-Use Liquid Losartan Available Through Major U.S. Wholesalers

10 days ago - By: Scienture Holdings, Inc.

SCIENTURE Holdings Announces Full Repayment and Conversion of Outstanding Debentures, Strengthening Balance Sheet

17 days ago - By: Scienture Holdings, Inc.

SCIENTURE Secures Multiple Commercial GPO Agreements, Expanding U.S. Market Access for Arbli™ (losartan potassium) to more than 2500 Healthcare Institutions

17 days ago - By: Benzinga

EXCLUSIVE: Scienture Secures Hypertension Drug Purchase Agreements With 2,500 Healthcare Institutions

a month ago - By: Scienture Holdings, Inc.

SCIENTURE Secures PBM-Led GPO Rebate Agreement to Drive Expanded Commercial Coverage and Formulary Access for Arbli™(losartan potassium) in the $256M U.S. Losartan Market

a month ago - By: Benzinga

EXCLUSIVE: Scienture Secures PBM-Led Rebate Agreement To Position Hypertension Drug For Rapid Adoption In US Market

2 months ago - By: Scienture Holdings, Inc.

Scienture Holdings, Inc. Announces Pricing of $3.9 Million Registered Direct Offering of Common Stock

2 months ago - By: Scienture Holdings, Inc.

SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.

3 months ago - By: Scienture Holdings, Inc.

Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding

3 months ago - By: Scienture Holdings, Inc.

Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements

4 months ago - By: Scienture Holdings, Inc.

Scienture Holdings Announces Cancelation of ELOC

5 months ago - By: Scienture Holdings, Inc.

SCIENTURE Announces Executive Leadership Transition

5 months ago - By: Scienture Holdings, Inc.

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.

6 months ago - By: Scienture Holdings, Inc.

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

6 months ago - By: Scienture Holdings, Inc.

SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.

7 months ago - By: Scienture Holdings, Inc.

Scienture Holdings, Inc. Issues Annual Letter to Shareholders

7 months ago - By: Scienture Holdings, Inc.

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization

7 months ago - By: Scienture Holdings, Inc.

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days

7 months ago - By: Scienture Holdings, Inc.

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.